DelveInsight reports that the Myelodysplastic Syndrome (MDS) pipeline includes over 120 key companies actively developing more than 125 therapeutic candidates.
Myelodysplastic Syndrome Overview:
Myelodysplastic syndrome (MDS) is a heterogeneous group of blood cancers characterized by clonal disorders of hematopoietic stem cells, leading to abnormal cell development (dysplasia) and ineffective blood cell production in the bone marrow. In some cases, MDS can progress to acute myeloid leukemia (AML). It is most commonly diagnosed in individuals over 65 and is associated with reduced levels of red blood cells, white blood cells, and platelets. The severity and symptoms of MDS can vary widely among patients.
The condition can arise from multiple factors, including environmental exposures such as benzene or radiation, prior chemotherapy, or idiopathic causes, particularly in older adults. Certain inherited or acquired bone marrow failure syndromes, like Fanconi anemia and acquired aplastic anemia, may increase the risk of MDS or mimic its features.
MDS can occur spontaneously (de novo) or as a result of other conditions or treatments, referred to as treatment-related MDS. Use of drugs such as alkylating agents or topoisomerase II inhibitors has been linked to MDS, typically developing 2 to 7 years post-treatment. The disease often involves genetic and chromosomal abnormalities, either present initially or arising from these risk factors. Over 80% of patients exhibit such abnormalities, which may include chromosome translocations or aneuploidy (chromosomal gains or losses).
Download our report @ https://www.delveinsight.com/report-store/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Myelodysplastic Syndrome Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Myelodysplastic Syndrome Therapeutics Market.
Key Takeaways from the Myelodysplastic Syndrome Pipeline Report
-
DelveInsight’s report on the Myelodysplastic Syndrome (MDS) pipeline highlights a dynamic landscape, with over 120 companies actively developing more than 125 therapeutic candidates.
-
In June 2024, the FDA approved imetelstat (Rytelo) for adults with low- to intermediate-1 risk MDS who have transfusion-dependent anemia requiring four or more red blood cell units over eight weeks and who have not responded to, or are ineligible for, erythropoiesis-stimulating agents.
-
Leading companies advancing MDS treatments include Novartis, Syros Pharmaceuticals, Curis, Ryvu Therapeutics, Chia Tai Tianqing Pharmaceutical Group, Amgen, Sanofi, Forma Therapeutics, Agios Pharmaceuticals, AbbVie, Daiichi Sankyo Company, Geron Corporation, Astex Pharmaceuticals, Jazz Pharmaceuticals, Maxinovel Pty., Ltd., Mabwell (Shanghai) Bioscience Co., Ltd., BeiGene, Ellipses Pharma, Treadwell Therapeutics, Bellicum Pharmaceuticals, and others.
-
Notable MDS pipeline therapies in development include Tamibarotene, CA-4948, RVU120, MNV-201, among several additional candidates.
Myelodysplastic Syndrome Pipeline Analysis
The Myelodysplastic Syndrome pipeline insights report 2025, provides insights into:
-
Provides comprehensive insights into key companies developing therapies in the Myelodysplastic Syndrome Market.
-
Categorizes Myelodysplastic Syndrome therapeutic companies by development stage: early, mid, and late-stage.
-
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
-
Reviews emerging Myelodysplastic Syndrome drugs under development based on:
-
Stage of development
-
Myelodysplastic Syndrome Route of administration
-
Target receptor
-
Monotherapy vs. combination therapy
-
Myelodysplastic Syndrome Mechanism of action
-
Molecular type
-
-
Offers detailed analysis of:
-
Company-to-company and company-academia collaborations
-
Myelodysplastic Syndrome Licensing agreements
-
Funding and investment activities supporting future Myelodysplastic Syndrome market advancement.
-
Request for a sample report @ https://www.delveinsight.com/sample-request/myelodysplastic-syndrome-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Myelodysplastic Syndrome Emerging Drugs
-
Tamibarotene: Syros Pharmaceuticals
-
CA-4948: Curis
-
RVU120: Ryvu Therapeutics
-
MNV-201: Minovia Therapeutics
Myelodysplastic Syndrome Companies
More than 120 leading companies are actively developing therapies for Myelodysplastic Syndrome (MDS), with Syros Pharmaceuticals advancing a drug candidate to the most advanced stage, Phase III clinical trials.
DelveInsight’s report covers around 125+ products under different phases of Myelodysplastic Syndrome clinical trials like
-
Myelodysplastic Syndrome Late stage Therapies (Phase III)
-
Myelodysplastic Syndrome Mid-stage Therapies (Phase II)
-
Myelodysplastic Syndrome Early-stage Therapies (Phase I)
-
Myelodysplastic Syndrome Pre-clinical and Myelodysplastic Syndrome Discovery stage Therapies
-
Myelodysplastic Syndrome Discontinued & Inactive Therapies
Myelodysplastic Syndrome pipeline report provides the Myelodysplastic Syndrome therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
-
Intravenous
-
Subcutaneous
-
Oral
-
Intramuscular
Myelodysplastic Syndrome Products have been categorized under various Molecule types such as
-
Monoclonal antibody
-
Small molecule
-
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Myelodysplastic Syndrome Therapies and Key Myelodysplastic Syndrome Companies: Myelodysplastic Syndrome Clinical Trials and recent advancements
Myelodysplastic Syndrome Pipeline Therapeutic Assessment
• Myelodysplastic Syndrome Assessment by Product Type
• Myelodysplastic Syndrome By Stage
• Myelodysplastic Syndrome Assessment by Route of Administration
• Myelodysplastic Syndrome Assessment by Molecule Type
Download Myelodysplastic Syndrome Sample report to know in detail about the Myelodysplastic Syndrome treatment market @ Myelodysplastic Syndrome Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Myelodysplastic Syndrome Current Treatment Patterns
4. Myelodysplastic Syndrome - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Myelodysplastic Syndrome Late-Stage Products (Phase-III)
7. Myelodysplastic Syndrome Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Myelodysplastic Syndrome Discontinued Products
13. Myelodysplastic Syndrome Product Profiles
14. Myelodysplastic Syndrome Key Companies
15. Myelodysplastic Syndrome Key Products
16. Dormant and Discontinued Products
17. Myelodysplastic Syndrome Unmet Needs
18. Myelodysplastic Syndrome Future Perspectives
19. Myelodysplastic Syndrome Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Myelodysplastic Syndrome Pipeline Reports Offerings
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
